PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2020
CASE
AUTH/3432/12/20 GlaxoSmithKline

GSK respiratory promotion: meeting invites missing mandatory info and asthma implication for Trelegy (AUTH/3432/12/20)

PMCPA found breaches for GSK respiratory materials: meeting invitations omitted non-proprietary names/black triangles/AE statement, one invite implied Trelegy was licensed for asthma,…

2021
CASE
AUTH/3479/2/21 Almirall

Almirall: UK employee β€˜liked’ global LinkedIn post, triggering UK Code breaches for public promotion and lack of certification/PI (AUTH/3479/2/21)

A senior UK employee β€˜liked’ a global LinkedIn post naming tildrakizumab/Ilumetri and 5-year efficacy/safety. Panel found this proactively disseminated promotion (incl to…

2021
CASE
AUTH/3495/3/21 Sanofi

Sanofi: bonus scheme slides on e-permissions ruled uncertified briefing material (AUTH/3495/3/21)

Anonymous employee alleged pressure to obtain HCP email consent (e-permissions). PMCPA found bonus-scheme slides were briefing material and should have been certified…

2021
CASE
AUTH/3568/10/21 Roche Products

Roche voluntary admission: Gazyvaro nurse leavepiece contained a 10x dosing typo (AUTH/3568/10/21)

A certified Gazyvaro nurse leavepiece listed Cycle 1 Day 1 dose as 1000mg instead of 100mg. PMCPA ruled it inaccurate/misleading, not high…

2021
CASE
AUTH/3519/5/21 Pfizer ⭐ Case of the Week

Pfizer press release on COVID-19 vaccine efficacy ruled misleading for omitting absolute risk context (AUTH/3519/5/21)

PMCPA found Pfizer’s 2 Dec 2020 COVID-19 vaccine press release breached Clause 7.2 and 9.1 for presenting relative risk reduction without sufficient…

2021
CASE
AUTH/3523/6/21 Novo Nordisk

AUTH/3523/6/21: Novo Nordiskβ€”LinkedIn post about early-phase pipeline (No breach)

Complaint about a third-party contractor’s LinkedIn post linking to Novo Nordisk’s R&D pipeline page. Panel found the post in scope of the…

2021
CASE
AUTH/3573/10/21 GlaxoSmithKline

GSK corporate website: investor page wording seen as public promotion of POMs (AUTH/3573/10/21)

A health professional complained about GSK’s pipeline and investor webpages. Pipeline page was ruled non-promotional, but investor page wording implied promotional claims…

2021
CASE
AUTH/3594/12/21 Daiichi-Sankyo UK

Daiichi Sankyo: non–arm’s length patient organisation cholesterol campaign and non-compliant abbreviated ad (AUTH/3594/12/21)

Disease awareness campaign with a patient organisation was treated as non–arm’s length sponsorship, triggering responsibility, certification and disclosure failures. Separate MIMS abbreviated…

2023
CASE
AUTH/3847/11/23 Novo Nordisk

Novo Nordisk voluntary admission: ~Β£7.8m undisclosed transfers of value (2020–2022) and public reprimand (AUTH/3847/11/23)

Novo Nordisk admitted failing to disclose ~Β£7.8m in transfers of value (2020–2022) due to inconsistent SAP vendor tagging. Multiple disclosure clauses breached…

2022
CASE
AUTH/3634/4/22 Daiichi-Sankyo UK ⭐ Case of the Week

AUTH/3634/4/22: Complainant v Daiichi Sankyo β€” Edoxaban (Lixiana) initiation leavepiece (no breach on narrow availability point)

Complaint said an edoxaban initiation leavepiece omitted hepatic considerations. Panel had concerns but ruled no breach because there was no evidence it…

2022
CASE
AUTH/3654/5/22 Novartis Pharmaceuticals UK

Novartis: Entresto symposium video on learned society website lacked prescribing information and key initiation thresholds (AUTH/3654/5/22)

A post-conference promotional video for Entresto hosted on a learned society website omitted prescribing information and failed to state key initiation limits…

2022
CASE
AUTH/3670/6/22 Novartis Pharmaceuticals UK

Novartis: Leqvio webinar registration pageβ€”adverse event reporting statement not sufficiently prominent (AUTH/3670/6/22)

Novartis breached the ABPI Code after a Leqvio webinar registration page displayed the adverse event reporting statement in a position/font size that…

2022
CASE
AUTH/3689/8/22 CSL Vifor

CSL Vifor voluntary admission: uncertified Ferinject banners shown to UK HCPs via ESC-HFA/Medscape (AUTH/3689/8/22)

At ESC-HFA 2022, Ferinject banner ads ran for 60 days on the congress site/Medscape and reached UK HCPs unintentionally. UK signatory certification…

2022
CASE
AUTH/3697/10/22 AstraZeneca

AUTH/3697/10/22: AstraZeneca symposium influenza vaccine comments and slide approval – No breach

Complaint about symposium slides allegedly lacking job codes and a speaker’s β€˜mismatch of the vaccine’ comment. PMCPA ruled no breach of Clauses…

2023
CASE
AUTH/3755/3/23 Novo Nordisk ⭐ Case of the Week

AUTH/3755/3/23: Health Professional v Novo Nordisk β€” funding alleged to induce prescribing (No breach)

Complaint alleged Novo Nordisk funded an obesity practitioner’s salary to induce prescribing and influenced local liraglutide criteria. Panel and Appeal Board found…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training